Downregulation of microRNA-21 expression restrains non-small cell lung cancer cell proliferation and migration through upregulation of programmed cell death 4

Cancer Gene Therapy

Volumn 22, Issue 1, 2015, Pages 23-29

  Yang, Y ^a   Meng, H ^a   Peng, Q ^a   Yang, X ^a   Gan, R ^a   Zhao, L ^a   Chen, Z ^a   Lu, J ^a,b,c   Meng, Q H ^d  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c Zhejiang Provincial Key Laboratory of Medical Genetics   (China)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOCYTE ANTIGEN; MEMBRANE RECEPTOR; MESSENGER RNA; MICRORNA 21; PROGRAMMED CELL DEATH 4; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; MICRORNA; MIRN21 MICRORNA, HUMAN; PDCD4 PROTEIN, HUMAN; RNA BINDING PROTEIN;

A549 CELL LINE; ADULT; APOPTOSIS; ARTICLE; CELL INVASION ASSAY; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; AGED; CANCER GRADING; CANCER STAGING; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

AGED; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; RNA INTERFERENCE; RNA-BINDING PROTEINS;

EID: 84921890618     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2014.66     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians 2013; 63: 11-30.
2. Wood AJ, Spira A, Ettinger DS. Multidisciplinary management of lung cancer. New England Journal of Medicine 2004; 350: 379-392.
3. Ponn RB, Lo Cicero J III, Daly BD. Surgical treatment of non-small cell lung cancer. General thoracic surgery 2005; 6: 1548-1587.
4. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2009; 27: 3277-3283.
5. Almeida MI, Reis RM, Calin GA. MicroRNA history: discovery, recent applications, and next frontiers. Mutation research 2011; 717: 1-8.
6. Munker R, Calin GA. MicroRNA profiling in cancer. Clinical science 2011; 121: 141-158.
7. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nature Reviews Genetics 2010; 11: 597-610.
8. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annual review of medicine 2009; 60: 167-179.
9. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nature reviews. Clinical oncology 2011; 8: 467-477.
10. Di Leva G, Croce CM. Roles of small RNAs in tumor formation. Trends in molecular medicine 2010; 16: 257-267.
11. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y et al. Serum MicroRNA signatures identified in a genome-wide serum MicroRNA expression profiling predict survival of non-small-cell lung cancer. Journal of Clinical Oncology 2010; 28: 1721-1726.
12. Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America 2006; 103: 2257-2261.
13. Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. Journal of cellular and molecular medicine 2009; 13: 39-53.
14. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer research 2009; 69: 7165-7169.
15. Darido C, Georgy SR, Wilanowski T, Dworkin S, Auden A, Zhao Q et al. Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis. Cancer cell 2011; 20: 635-648.
16. Folini M, Gandellini P, Longoni N, Profumo V, Callari M, Pennati M et al. miR-21: an oncomir on strike in prostate cancer. Molecular cancer 2010; 9 : 12.
17. Lankat-Buttgereit B, Goke R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biology of the Cell 2009; 101: 309-317.
18. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 2011; 57: 833-840.
19. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nature methods 2007; 4: 721-726.
20. Lu J, Ji J, Meng H, Wang D, Jiang B, Liu L et al. The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats. Cardiovasc Diabetol 2013; 12: 58.
21. Yu S-L, Chen H-Y, Chang G-C, Chen C-Y, Chen H-W, Singh S et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer cell 2008; 13: 48-57.
22. Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in nonsmall cell lung cancer (NSCLC). Clinica chimica acta; international journal of clinical chemistry 2010; 411: 846-852.
23. Liu Z-L, Wang H, Liu J, Wang Z-X. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo-or radioresistance in non-small cell lung cancer cells by targeting PTEN. Molecular and cellular biochemistry 2013; 372: 35-45.
24. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A et al. Reprogramming of miRNA networks in cancer and leukemia. Genome research 2010; 20: 589-599.
25. Wang Q, Zhang Y, Yang HS. Pdcd4 knockdown up-regulates MAP4K1 expression and activation of AP-1 dependent transcription through c-Myc. Biochimica et biophysica acta 2012; 1823: 1807-1814.
26. Bitomsky N, Bohm M, Klempnauer KH. Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun. Oncogene 2004; 23: 7484-7493.
27. Ma X, Kumar M, Choudhury SN, Buscaglia LEB, Barker JR, Kanakamedala K et al. Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proceedings of the National Academy of Sciences 2011; 108: 10144-10149.
28. Chang JH, Cho YH, Sohn SY, Choi JM, Kim A, Kim YC et al. Crystal structure of the eIF4A-PDCD4 complex. Proceedings of the National Academy of Sciences 2009; 106: 3148-3153.
29. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-2136.
30. Gaur AB, Holbeck SL, Colburn NH, Israel MA. Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. Neuro-oncology 2011; 13: 580-590.
31. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010; 18: 282-293.
32. Leupold JH, Yang HS, Colburn NH, Asangani I, Post S, Allgayer H. Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene 2007; 26: 4550-4562.
33. Jung E-J, Calin GA. The meaning of 21 in the microRNA world: perfection rather than destruction? Cancer cell 2010; 18: 203-205.